ELOC

Overview

ELOC (Elongin C; previously TCEB1) is a subunit of the Cullin-RING E3 ubiquitin ligase complex that, together with VHL, targets HIF-alpha for degradation. Somatic mutations in ELOC have been identified as recurrent drivers in VHL-wild-type clear cell renal cell carcinoma (ccRCC), providing an alternative route to HIF activation in the absence of VHL loss.

Alterations observed in the corpus

  • Cited as a recurrently mutated driver gene in VHL-wild-type ccRCC; truncal-versus-branch mutation status was not directly addressed in a 10-tumor multi-region sequencing cohort PMID:24487277
  • ELOC (paper-era symbol TCEB1) is a KIRC significantly mutated gene (SMG) uniquely called by MutSig2CV (not recovered by MuSiC2) in the TCGA MC3 MAF open-access pan-cancer analysis; it encodes an elongin C subunit of the VHL-E3 ubiquitin ligase complex, consistent with its known tumor suppressor role in clear-cell renal cell carcinoma PMID:29596782.

Cancer types (linked)

Co-occurrence and mutual exclusivity

  • Mutations tend to occur in VHL-wild-type ccRCC, providing an alternative mechanism for HIF pathway activation PMID:24487277

Therapeutic relevance

Open questions

  • Whether ELOC-mutant VHL-wild-type tumors respond differently to HIF-targeting or mTOR therapies compared to VHL-mutant ccRCC is unresolved.

Sources

This page was processed by entity-page-writer on 2026-05-11. - PMID:29596782

This page was processed by wiki-cli on 2026-05-15.